{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:56:58Z","timestamp":1792612618865,"version":"4.5.0"},"reference-count":37,"publisher":"The Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>Context:<\/jats:title>\n                  <jats:p>The diagnosis of familial hypercholesterolemia (FH) can be made using the Dutch Lipid Clinic Network criteria. This employs the personal and family history of premature coronary artery disease and hypercholesterolemia and the presence of a pathogenic mutation in the low-density lipoprotein receptor (LDLR) and apolipoprotein B (APOB) genes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>We employed this tool to investigate the prevalence of FH and the associations between FH and coronary artery disease and cholesterol-lowering medication in the Copenhagen General Population Study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting:<\/jats:title>\n                  <jats:p>The study was of an unselected, community-based population comprising 69,016 participants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures:<\/jats:title>\n                  <jats:p>FH (definite\/probable) was defined as a Dutch Lipid Clinic Network score higher than 5. Coronary artery disease was myocardial infarction or angina pectoris.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>The prevalence of FH was 0.73% (one in 137). Of participants with FH, 20% had an LDLR or APOB mutation. The prevalence of coronary artery disease among FH participants was 33%. Only 48% of subjects with FH admitted to taking cholesterol-lowering medication. The odds ratio for coronary artery disease off cholesterol-lowering medication was 13.2 (10.0\u201317.4) in definite\/probable FH compared with non-FH subjects, after adjusting for age, gender, body mass index, hypertension, metabolic syndrome and diabetes, and smoking. The corresponding adjusted odds ratio for coronary artery disease in FH subjects on cholesterol-lowering medication was 10.3 (7.8\u201313.8).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>The prevalence of FH appears to be higher than commonly perceived in a general population of white Danish individuals, with at least half of affected subjects not receiving cholesterol-lowering medication. The very high risk of coronary artery disease irrespective of use of medication reflects the extent of underdiagnosis and undertreatment of FH in the community and primary care.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2012-1563","type":"journal-article","created":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T18:55:14Z","timestamp":1352141714000},"page":"3956-3964","source":"Crossref","is-referenced-by-count":568,"title":["Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication"],"prefix":"10.1210","volume":"97","author":[{"given":"Marianne","family":"Benn","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry (M.B., B.G.N.), DK-2730 Herlev, Denmark"},{"name":"The Copenhagen General Population Study (M.B., A.T.-H., B.G.N.), Herlev Hospital, Copenhagen University Hospital, DK-2730 Herlev, Denmark"},{"name":"Faculty of Health Sciences (M.B., A.T.-H., B.G.N.), University of Copenhagen, DK-1455 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[{"name":"School of Medicine and Pharmacology (G.F.W.), Lipid Disorders Clinic, Royal Perth Hospital, University of Western Australia, Perth WA6000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tybjaerg-Hansen","sequence":"additional","affiliation":[{"name":"The Copenhagen General Population Study (M.B., A.T.-H., B.G.N.), Herlev Hospital, Copenhagen University Hospital, DK-2730 Herlev, Denmark"},{"name":"Department of Clinical Biochemistry (A.T.-H.), Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry (M.B., B.G.N.), DK-2730 Herlev, Denmark"},{"name":"The Copenhagen General Population Study (M.B., A.T.-H., B.G.N.), Herlev Hospital, Copenhagen University Hospital, DK-2730 Herlev, Denmark"},{"name":"Faculty of Health Sciences (M.B., A.T.-H., B.G.N.), University of Copenhagen, DK-1455 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071619595218000_B1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ncpcardio0941","article-title":"Familial hypercholesterolemia: a missed opportunity in preventive medicine.","volume":"4","author":"Watts","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"2020071619595218000_B2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/aje\/kwh237","article-title":"Familial hypercholesterolemia and coronary heart disease: a HuGE association review.","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"key":"2020071619595218000_B3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/aje\/kwh236","article-title":"Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review.","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"key":"2020071619595218000_B4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia.","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"2020071619595218000_B5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9149(93)90155-6","article-title":"Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics.","volume":"72","author":"Williams","year":"1993","journal-title":"Am J Cardiol"},{"key":"2020071619595218000_B6","article-title":"Identification and management of familial hypercholesterolaemia","volume-title":"NICE clinical guideline 71","author":"National Collaborating Centre for Primary Care","year":"2008"},{"key":"2020071619595218000_B7","article-title":"Familial hypercholesterolaemia (FH)","volume-title":"Report of a second WHO consultation","author":"World Health Organization","year":"1999"},{"key":"2020071619595218000_B8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/01.mol.0000174152.76554.d6","article-title":"Implementation of cascade testing for the detection of familial hypercholesterolaemia.","volume":"16","author":"Hadfield","year":"2005","journal-title":"Curr Opin Lipidol"},{"key":"2020071619595218000_B9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.atherosclerosis.2011.06.012","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).","volume":"217","author":"Catapano","year":"2011","journal-title":"Atheroscler"},{"key":"2020071619595218000_B10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.atherosclerosissup.2011.06.001","article-title":"Familial hypercholesterolaemia: a model of care for Australasia.","volume":"12","author":"Watts","year":"2011","journal-title":"Atheroscler Suppl"},{"key":"2020071619595218000_B11","first-page":"18","article-title":"[The practice guideline \u2018Diagnosis and treatment of familial hypercholesterolaemia\u2019 of the Dutch Health Care Insurance Board].","volume":"150","author":"Walma","year":"2006","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2020071619595218000_B12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0021-9150(99)00158-6","article-title":"Spectrum of LDL receptor gene mutations in Denmark: implications for molecular diagnostic strategy in heterozygous familial hypercholesterolemia.","volume":"146","author":"Jensen","year":"1999","journal-title":"Atherosclerosis"},{"key":"2020071619595218000_B13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.atherosclerosis.2004.12.001","article-title":"The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population.","volume":"180","author":"Damgaard","year":"2005","journal-title":"Atherosclerosis"},{"key":"2020071619595218000_B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.","volume":"168","author":"Marks","year":"2003","journal-title":"Atherosclerosis"},{"key":"2020071619595218000_B15","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jacl.2011.03.452","article-title":"Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.","volume":"5","author":"Hopkins","year":"2011","journal-title":"J Clin Lipidol"},{"key":"2020071619595218000_B16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/bmj.321.7254.148","article-title":"Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study.","volume":"321","author":"Neil","year":"2000","journal-title":"BMJ"},{"key":"2020071619595218000_B17","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia.","volume":"303","author":"Scientific Steering Committee SBRG","year":"1991","journal-title":"BMJ"},{"key":"2020071619595218000_B18","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/bmj.322.7293.1019","article-title":"Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study.","volume":"322","author":"Sijbrands","year":"2001","journal-title":"BMJ"},{"key":"2020071619595218000_B19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"2020071619595218000_B20","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","article-title":"Genetically elevated C-reactive protein and ischemic vascular disease.","volume":"359","author":"Zacho","year":"2008","journal-title":"N Engl J Med"},{"key":"2020071619595218000_B21","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/1403494811414241","article-title":"The paradox of public health genomics: definition and diagnosis of familial hypercholesterolaemia in three European countries.","volume":"39","author":"Aarden","year":"2011","journal-title":"Scand J Public Health"},{"key":"2020071619595218000_B22","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias.","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"2020071619595218000_B23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"2020071619595218000_B24","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/00004872-200311000-00002","article-title":"2003 World Health Organization (WHO)\/International Society of Hypertension (ISH) statement on management of hypertension.","volume":"21","author":"Whitworth","year":"2003","journal-title":"J Hypertens"},{"key":"2020071619595218000_B25","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"2020071619595218000_B26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/01.ATV.0000149380.94984.f0","article-title":"Phenotype of heterozygotes for low-density lipoprotein receptor mutations identified in different background populations.","volume":"25","author":"Tybjaerg-Hansen","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020071619595218000_B27","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/MOL.0b013e32830636e5","article-title":"What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia?","volume":"19","author":"Humphries","year":"2008","journal-title":"Curr Opin Lipidol"},{"key":"2020071619595218000_B28","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"key":"2020071619595218000_B29","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.","volume":"29","author":"Neil","year":"2008","journal-title":"Eur Heart J"},{"key":"2020071619595218000_B30","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.108.804146","article-title":"Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction.","volume":"118","author":"Langsted","year":"2008","journal-title":"Circulation"},{"key":"2020071619595218000_B31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1373\/clinchem.2010.160093","article-title":"Whither the lipid profile: feast, famine, or no free lunch?","volume":"57","author":"Watts","year":"2011","journal-title":"Clin Chem"},{"key":"2020071619595218000_B32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1567-5688(03)00024-2","article-title":"Silent ischaemia in familial hypercholesterolemia.","volume":"4","author":"Descamps","year":"2003","journal-title":"Atheroscler Suppl"},{"key":"2020071619595218000_B33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"key":"2020071619595218000_B34","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/HJR.0b013e3283383f30","article-title":"EUROASPIRE III Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.","volume":"17","author":"Kotseva","year":"2010","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2020071619595218000_B35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","article-title":"EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.","volume":"16","author":"Kotseva","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2020071619595218000_B36","first-page":"A4470","article-title":"Only a fraction of patients with ischaemic diseases or diabetes are treated to recommended target values for plasma lipids.","volume":"59","author":"Siggaard-Andersen","year":"2012","journal-title":"Dan Med J"},{"key":"2020071619595218000_B37","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2011.03.453","article-title":"Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.","volume":"5","author":"Daniels","year":"2011","journal-title":"J Clin Lipidol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/97\/11\/3956\/10746504\/jcem3956.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/97\/11\/3956\/10746504\/jcem3956.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T04:57:51Z","timestamp":1594961871000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/97\/11\/3956\/2836467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,1]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2012-1563","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,1]]}}}